Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346341 | 0.89 | PTP4A1 (0.49) | THRBMAPTPTP4A1GAAPKM | |
| SCHEMBL7073645 | 0.84 | HSP90AB1 (0.54) | THRBGAATHRATSHRSMN1; SMN2 | |
| SCHEMBL11221411 | 0.82 | ALDH1A1 (0.42) | MAPTGAAPKMCYP4Z1TSHR | |
| SCHEMBL12428008 | 0.81 | ALOX5 (0.52) | MAPTGAATSHRALOX15HSD17B10 | |
| SCHEMBL24690441 | 0.80 | MAPT (0.47) | MAPTGAAPKMCYP4Z1TSHR | |
| SCHEMBL18524140 | 0.80 | MAPT (0.48) | MAPTGAAPKMCYP4Z1TSHR | |
| SCHEMBL23218343 | 0.79 | GAA (0.45) | MAPTPTP4A1GAAPKM | |
| SCHEMBL11147975 | 0.78 | THRB (0.46) | THRBMAPTGAACYP4Z1THRA | |
| SCHEMBL15494202 | 0.77 | THRB (0.48) | THRBMAPTTHRASMN1; SMN2 | |
| SCHEMBL7074178 | 0.77 | CA2 (0.53) | THRBMAPTGAATHRATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234954-B1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS INC (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2234954-B1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| WO-2013106678-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013106328-A1 | TETRASUBSTITUTED BENZENES FOR TREATMENT OF EARLY ONSET ALZHEIMER'S DISEASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| US-8217064-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217064-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217064-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| CN-101945848-A | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS INC | 2011-01-12 | — | — | CN | disclosed |
| EP-2234954-A1 | TETRASUBSTITUTED BENZENES | Envivo Pharmaceuticals, Inc. (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| WO-2009086277-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086277-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364641-A1 | Tetrasubstituted Benzenes | BACE1, BACE2, PSEN1 | THRB 833/4885MAPT 41/4885PTP4A1 947/4885 |
| US-20090299072-A1 | Tetrasubstituted Benzenes | BACE1, BACE2, PSEN1 | THRB 833/4885MAPT 41/4885PTP4A1 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.